Titan Biotech Limited has announced the opening of a special window for transfer and dematerialization of physical securities, providing investors with a crucial opportunity to modernize their shareholdings and ensure better security of their investments.

SEBI Initiative for Investor Protection

Following SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD-I/3750/2026 dated January 30, 2026, the Securities and Exchange Board of India has opened another special window to facilitate ease of investing for investors and safeguard their rights in securities purchased prior to April 1, 2019. This regulatory initiative aims to encourage the conversion of physical securities to electronic form, enhancing investor protection and market efficiency.

Special Window Timeline and Coverage

The special window provides comprehensive coverage for various scenarios, including transfer requests that were submitted earlier but were rejected, returned, or not attended to due to deficiencies in documents, process, or other issues. This inclusive approach ensures that investors who faced difficulties in previous attempts can now complete their transactions successfully.

Process and Documentation Requirements

Investors who were unable to meet the earlier deadline of January 6, 2026, can now avail of this opportunity by furnishing the requisite documents to the company's designated Registrar and Transfer Agent. The process has been streamlined to ensure smooth execution of transfer and dematerialization requests.

Company Information and Accessibility

Titan Biotech Limited, incorporated under CIN: L74999RJ1992PLC013387, operates as an ISO 9001:2015 certified company with its corporate office located at 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034. The company maintains manufacturing units in Rajasthan and provides comprehensive information about this initiative on its website at www.titanbiotechltd.com .

The announcement was made by Charanjit Singh, Company Secretary and Compliance Officer (M. No.: A12726), emphasizing the company's commitment to facilitating smooth transitions for its shareholders. This initiative represents a significant step toward modernizing shareholding patterns and ensuring enhanced security for investor holdings in the digital age.

Titan Biotech Limited has announced that its Board of Directors will convene on February 12, 2026, to review and approve the company's third quarter financial results for FY26. The meeting represents a key milestone in the company's quarterly reporting cycle and regulatory compliance obligations.

Board Meeting Details

The board meeting has been scheduled with specific parameters and agenda items that reflect standard corporate governance practices:

Financial Results Scope

The board will consider and approve comprehensive financial statements covering multiple reporting formats:

• Unaudited standalone financial results for the third quarter ended December 31, 2025
• Unaudited consolidated financial results for the same period
• Any other business matters with the Chair's permission

Trading Window Restrictions

Titan Biotech Limited has implemented trading restrictions in accordance with regulatory requirements. The trading window for designated persons closed on January 1, 2026, following prior intimation dated December 22, 2025. This closure aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Charanjit Singh has signed the formal intimation to BSE Limited, ensuring transparency and adherence to listing requirements.

The notification was submitted to BSE Limited on February 3, 2026, providing adequate advance notice to stakeholders and market participants about the upcoming board meeting and financial results announcement.